Diabetes mellitus may affect the long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after liver transplantation

Table 2 Antiviral prophylaxis before and after liver transplantation for hepatitis B virus reinfection

Patients with high risk of HBV reinfection[HBV-DNA ≥ 105 copies/mL or HBeAg(+)]	Patients with low risk of HBV reinfection[HBV-DNA < 105 copies/mL or HBeAg(-)]
Pre-LT: nucleoside analogues, qd 2-4 w	Pre-LT: nucleoside analogues, qd 0-2 w
Intraoperative: HBIG 4000 IU, iv	Intraoperative: HBIG 2000 IU, iv
Post-LT: HBIG 1000 IU, iv, qd, 1-7 d	Post-LT: HBIG 1000 IU, iv, qd, 1-7d
After 7 d, HBIG 1000 IU, iv, once a week; or HBIG 400 IU, im, qd or qod or twice a week. Adjust frequency of HBIG administration to reach target therapeutic concentration	After 7 d, HBIG 1000 IU, iv, once a week; or HBIG 400 IU, im, qd or qod or twice a week. Adjust frequency of HBIG administration to reach target therapeutic concentration
Target therapeutic concentration post-LT	Target therapeutic concentration post-LT
≤ 6 mo post-LT: anti-HBs titer ≥ 500 IU/L	≤ 6 mo post-LT: anti-HBs titer ≥ 300 IU/L
6-12 mo post-LT: anti-HBs titer ≥ 200 IU/L	6-12 mo post-LT: anti-HBs titer ≥ 200 IU/L
≥ 12 mo post-LT: anti-HBs titer ≥ 100 IU/L	≥ 12 mo post-LT: anti-HBs titer ≥ 100 IU/L

HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen; LT: Liver transplantation.